Chiesi Nordic
Olav Fromm is an experienced professional in the pharmaceutical and life sciences sectors, currently serving as Managing Director and Country Manager for the Nordic Region at Chiesi Nordic since May 2012. In addition, Fromm has been a Board Member at Lif - de forskande läkemedelsföretagen since May 2021. Prior to these roles, Fromm owned Fromm Kommunikation AB, a consultancy specializing in sales and marketing within the Life Science field, from January 2011 to December 2017. Olav Fromm's earlier experience includes positions such as Product Manager for Immunology at Schering-Plough Pharmaceuticals and Brand Manager for Respiratory at Pfizer Pharmaceuticals. Fromm holds an MSc in International Business Administration from Linköping University, earned from 1991 to 1997.
This person is not in any teams
Chiesi Nordic
1 followers
Chiesi is an international, privately-owned pharmaceutical company with its Corporate Head Office based in Parma, Italy. Chiesi is dedicated to the research, development and sales of innovative, therapeutic prescription medicines in the fields of respiratory, neonatology, transplant medicine and rare diseases. Founded in 1935, as a family firm, today, Chiesi spans the globe, employing more than 5000 people in 26 affiliates worldwide and distributes its products in more than 70 countries. In the Nordics, Chiesi Pharma AB employs more than 50 dedicated employees, who are based out of our head office in Central Stockholm, the recently integrated Research and Development Centre at Lidingö outside Stockholm or are part of our experienced field-based sales teams. As with every part of the Chiesi group, we embrace a shared set of values and a common code of ethical conduct. This demands the highest standards of reliability, transparency, and individual accountability in everything we do. It emphasizes the importance of collaborative working, putting people first and exchanging knowledge. Implicit in all of these values is a responsible attitude to the social and environmental impact of our actions. Chiesi is entering important new therapy areas, such as organ transplantation and rare diseases, alongside our treatments for respiratory conditions.